A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma.

Trial Profile

A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Malignant thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2008 The expected completion date for this trial is now 1 Sep 2007.
    • 14 Nov 2007 Status changed from recruiting to completed.
    • 29 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top